$REGN News

Why Regeneron (REGN) Stock Is Trading Up Today

How Investors May Respond To Regeneron (REGN) EMA Fast-Track Review Of Otarmeni Gene Therapy

CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

Are Options Traders Betting on a Big Move in Regeneron Stock?

Regeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound? (Revised)

Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength (Revised)

Is Regeneron Pharmaceuticals Stock Underperforming the Dow?

Regeneron (REGN) Says EMA Accepted Review for Otarmeni Application

Regeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound?

Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak

Regeneron And Parabilis Target Undruggable Proteins As Valuation Draws Interest

Canaccord Cuts PT on Regeneron Pharmaceuticals (REGN), Cites a Disappointing Event

Are Wall Street Analysts Predicting Regeneron Pharmaceuticals Stock Will Climb or Sink?

Regeneron (REGN) Enters $2.32B Collaboration With Parabilis to Target ‘Undruggable’ Proteins

Regeneron R&D Updates Test Market View On Long Term Pipeline Value

Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss

Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis

Regeneron's Lynozyfic Shows 100% Complete Response And Rapid Biomarker Normalization In Phase 1/2 AL Amyloidosis Trial With Organ Function Improvement Signals; First Results From The Phase 1/2 LINKER-AL2 Trial To Be Detailed In An Asco Oral Presentation; The Phase 2 Portion Of The Trial With Registrational Intent Is Ongoing

Jim Cramer on Regeneron: “There Could Be Some More Downgrades”

$100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth This Much Today